Dynamic Technology Lab Private Ltd bought a new stake in Retrophin, Inc. (NASDAQ:RTRX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 8,521 shares of the biopharmaceutical company’s stock, valued at approximately $212,000.

Several other institutional investors and hedge funds have also modified their holdings of the company. SG Americas Securities LLC increased its holdings in shares of Retrophin by 1.8% in the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 146 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Retrophin by 1.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 30,520 shares of the biopharmaceutical company’s stock valued at $592,000 after purchasing an additional 290 shares during the period. Legal & General Group Plc increased its holdings in shares of Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 355 shares during the period. AJO LP increased its holdings in shares of Retrophin by 1.9% in the 2nd quarter. AJO LP now owns 59,681 shares of the biopharmaceutical company’s stock valued at $1,157,000 after purchasing an additional 1,094 shares during the period. Finally, Parametric Portfolio Associates LLC increased its holdings in shares of Retrophin by 3.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,471 shares of the biopharmaceutical company’s stock valued at $649,000 after purchasing an additional 1,200 shares during the period.

A number of brokerages have recently weighed in on RTRX. BidaskClub upgraded Retrophin from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. BMO Capital Markets reiterated a “buy” rating and issued a $44.00 target price on shares of Retrophin in a report on Friday, October 6th. ValuEngine downgraded Retrophin from a “hold” rating to a “sell” rating in a report on Monday, November 20th. Finally, Zacks Investment Research cut Retrophin from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 14th. Two investment analysts have rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $36.00.

Shares of Retrophin, Inc. (RTRX) opened at $21.55 on Friday. Retrophin, Inc. has a 12 month low of $15.55 and a 12 month high of $26.44. The company has a current ratio of 3.88, a quick ratio of 3.83 and a debt-to-equity ratio of 0.15.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.21). The firm had revenue of $40.34 million during the quarter, compared to the consensus estimate of $40.51 million. Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The company’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.09) EPS. equities research analysts anticipate that Retrophin, Inc. will post -1.25 EPS for the current fiscal year.

WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/08/dynamic-technology-lab-private-ltd-invests-212000-in-retrophin-inc-rtrx.html.

Retrophin Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Stock Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related stocks with our FREE daily email newsletter.